2024 IMSA WeatherTech LMP2 campaign beckons as the team withdraws from Petit Le Mans

JUPITER, Fla. (10 October 2023) – Sean Creech Motorsport (SCM) will not race in this weekend’s Motul Petit Le Mans, focusing instead on its 2024 IMSA WeatherTech SportsCar Championship program with the No. 33 Ligier JS P217.

With Lance Willsey unable to contest the 10-hour endurance classic due to a family emergency, the team – along with driver João Barbosa – now shifts its focus to its new Ligier JS P217 LMP2 car and the 2024 season, which begins with the Rolex 24 at Daytona just over 100 days from now.

The team recently completed the first test last week (full story here) and was highly encouraged about the early progress with the effectively all-new machine that is likely to be a unique package within the IMSA LMP2 landscape starting in 2024.

“Obviously we’re disappointed to not do Petit, but Lance’s family is what’s most important,” said team principal Sean Creech. “2023 is in the rearview mirror now. We’re well underway with our 2024 preparations, with the first test of the LMP2 car at Daytona last week – which went very well. We’ll continue testing the car over the next few months so we’re in a good position at Daytona.”

The 2024 IMSA WeatherTech SportsCar Championship season gets underway in January at Daytona International Speedway, with the Roar Before the Rolex 24 January 19-21, and the 61st Rolex 24 at Daytona taking the green flag Saturday, January 27, 2024.

SCM would like to thank partner Focal One for its continued support.

About SCM

Team leader Sean Creech has competed in a multitude of sports car series from 1990 until the present day, including Group C, IMSA GTP, WSC, Grand-Am, SRO World Challenge, and IMSA. SCM will contest the full WeatherTech SportsCar Championship in 2023 with João Barbosa and Lance Willsey.   https://seancreechmotorsport.com/

About Focal One

One in eight men will be diagnosed with prostate cancer during their lifetime in the United States. The Focal One® HIFU Prostate treatment offers patients a non-invasive outpatient procedure to target prostate tissue while avoiding the common side effects such as loss of urinary continence and sexual function. The Focal One treatment uses high-performance, high-intensity focused ultrasound (HIFU) to precisely target and ablate the prostate, allowing patients to quickly return to normal activities. http://www.focalone.com/ 

SCM Social Media

Instagram:    @seancreechms

Twitter:         @SeanCreechMS

Threads:        @seancreechms

Facebook:      Sean Creech Motorsport